LeMaitre Vascular, Inc. (NASDAQ:LMAT) Given Consensus Recommendation of “Moderate Buy” by Analysts

LeMaitre Vascular, Inc. (NASDAQ:LMAT) has earned a consensus rating of “Moderate Buy” from the six analysts that are presently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $68.20.

A number of equities research analysts have recently issued reports on LMAT shares. Barrington Research increased their price target on shares of LeMaitre Vascular from $66.00 to $69.00 and gave the stock an “outperform” rating in a report on Wednesday, February 28th. KeyCorp initiated coverage on shares of LeMaitre Vascular in a research report on Tuesday, February 6th. They set a “sector weight” rating for the company. Finally, StockNews.com downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Tuesday, April 16th.

LeMaitre Vascular Trading Up 2.3 %

Shares of LMAT stock opened at $64.23 on Wednesday. LeMaitre Vascular has a 12 month low of $44.27 and a 12 month high of $74.64. The stock has a market capitalization of $1.44 billion, a P/E ratio of 47.93, a PEG ratio of 2.73 and a beta of 0.87. The firm’s 50 day moving average is $65.21 and its 200 day moving average is $57.97.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Tuesday, February 27th. The medical instruments supplier reported $0.38 EPS for the quarter, topping analysts’ consensus estimates of $0.36 by $0.02. LeMaitre Vascular had a return on equity of 10.57% and a net margin of 15.56%. The firm had revenue of $48.90 million during the quarter, compared to analyst estimates of $49.01 million. During the same period last year, the company earned $0.25 earnings per share. The business’s revenue for the quarter was up 19.3% on a year-over-year basis. On average, equities analysts predict that LeMaitre Vascular will post 1.66 EPS for the current year.

LeMaitre Vascular Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 28th. Stockholders of record on Thursday, March 14th were given a dividend of $0.16 per share. The ex-dividend date was Wednesday, March 13th. This represents a $0.64 annualized dividend and a dividend yield of 1.00%. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.14. LeMaitre Vascular’s dividend payout ratio (DPR) is 47.76%.

Insider Buying and Selling

In other news, Director Lawrence J. Jasinski sold 5,110 shares of the company’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $67.50, for a total value of $344,925.00. Following the completion of the transaction, the director now directly owns 5,309 shares in the company, valued at approximately $358,357.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, CEO George W. Lemaitre sold 27,859 shares of LeMaitre Vascular stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $69.73, for a total value of $1,942,608.07. Following the transaction, the chief executive officer now owns 2,255,737 shares in the company, valued at approximately $157,292,541.01. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Lawrence J. Jasinski sold 5,110 shares of the business’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $67.50, for a total transaction of $344,925.00. Following the completion of the sale, the director now directly owns 5,309 shares of the company’s stock, valued at $358,357.50. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 114,036 shares of company stock worth $7,873,749. Corporate insiders own 12.40% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Conestoga Capital Advisors LLC grew its position in LeMaitre Vascular by 0.5% during the 4th quarter. Conestoga Capital Advisors LLC now owns 1,927,971 shares of the medical instruments supplier’s stock worth $109,432,000 after acquiring an additional 10,390 shares during the last quarter. Vanguard Group Inc. raised its holdings in LeMaitre Vascular by 2.5% during the 4th quarter. Vanguard Group Inc. now owns 1,548,870 shares of the medical instruments supplier’s stock valued at $87,914,000 after buying an additional 38,303 shares during the last quarter. Copeland Capital Management LLC boosted its position in LeMaitre Vascular by 2.3% during the 4th quarter. Copeland Capital Management LLC now owns 1,259,961 shares of the medical instruments supplier’s stock valued at $71,515,000 after buying an additional 28,720 shares during the period. Ranger Investment Management L.P. grew its holdings in LeMaitre Vascular by 1.5% in the 4th quarter. Ranger Investment Management L.P. now owns 912,503 shares of the medical instruments supplier’s stock worth $51,794,000 after acquiring an additional 13,681 shares during the last quarter. Finally, Congress Asset Management Co. MA increased its position in shares of LeMaitre Vascular by 12.0% in the first quarter. Congress Asset Management Co. MA now owns 666,083 shares of the medical instruments supplier’s stock valued at $44,201,000 after acquiring an additional 71,411 shares during the period. Hedge funds and other institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.